Get the Stockscreener App
1.50
7.53%
0.105
Zura Bio Ltd stock is traded at $1.50, with a volume of 471.12K.
It is up +7.53% in the last 24 hours and up +42.86% over the past month.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
See More
Previous Close:
$1.395
Open:
$1.37
24h Volume:
471.12K
Relative Volume:
0.65
Market Cap:
$102.56M
Revenue:
-
Net Income/Loss:
$-60.36M
P/E Ratio:
-0.3414
EPS:
-4.394
Net Cash Flow:
$-15.05M
1W Performance:
-8.54%
1M Performance:
+42.86%
6M Performance:
-20.21%
1Y Performance:
-60.11%
1-Day Range:
$1.345
$1.515
1-Week Range:
$1.345
$1.6994
52-Week Range:
$0.97
$5.07
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.50 | 86.62M | 0 | -60.36M | -15.05M | -4.394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Multi factor analysis applied to Zura Bio LimitedDaily Equity Signal Strength Summary Report - Newser
Published on: 2025-08-01 00:02:11 - Newser
What makes Zura Bio Limited stock price move sharplyAI Intraday Market Movement Prediction Tool - Newser
Why is Zura Bio Limited stock attracting strong analyst attentionSmart Portfolio Recommendation For Beginners - jammulinksnews.com
Chart based analysis of Zura Bio Limited trendsLong Term Stock Growth Plan Suggestions - Newser
Can machine learning forecast Zura Bio Limited recoveryAlgorithmic Prediction of Market Breakouts - Newser
Is Zura Bio Limited a growth stock or a value stockEntry Signal Guidance That Work - jammulinksnews.com
How Zura Bio Limited stock performs during market volatilityNext Day Momentum Stock Forecasting Report - Newser
What markets is Zura Bio Limited expanding into Is NEE.PRT stock a good long term investment optionPhenomenal capital appreciation - jammulinksnews.com
Is Zura Bio Limited Stock Overbought or Oversold RSI Indicator AnalysisShort-Term Upside Breakout Forecast System - Newser
What are Zura Bio Limited company’s key revenue driversStock Market Report For Consistent Profits - jammulinksnews.com
Is Zura Bio Limited a good long term investmentDynamic profit opportunities - PrintWeekIndia
Published on: 2025-07-25 23:30:16 - PrintWeekIndia
What analysts say about Zura Bio Limited stockConsistent high-yield stocks - jammulinksnews.com
What drives Zura Bio Limited stock priceLightning-fast growth - jammulinksnews.com
Zura Bio Limited Stock Analysis and ForecastFree Stock Selection - Autocar Professional
H.C. Wainwright reiterates Neutral rating on Zura Bio stock amid BAFF inhibitor concerns - Investing.com Australia
H.C. Wainwright reiterates Neutral rating on Zura Bio stock amid BAFF inhibitor concerns By Investing.com - Investing.com South Africa
3 Penny Stocks With Market Caps Over $70M Worth Watching - simplywall.st
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Zura Bio Surges 30% in Volatile Intraday Session: What's Fueling the Momentum? - AInvest
Jessica Chen - White & Case LLP
Why Zura Bio Limited stock attracts strong analyst attentionFree Access to Community with 300% Return - Newser
We're Not Very Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Rate - Yahoo Finance
The ZURA Stock Puzzle: Unraveling Zura Bio Ltd’s Fluctuating Performance - investchronicle.com
Zura Bio appoints Eric Hyllengren as CFO - MSN
Zura Bio names Eric Hyllengren as new CFO, effective July 7 - Investing.com
Zura Bio Announces Chief Financial Officer Transition - Business Wire
Zura Bio Limited(NasdaqCM: ZURA) dropped from Russell 2000 Dynamic Index - MarketScreener
Two Sigma Investments LP Decreases Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Analysts Set Expectations for Zura Bio FY2026 Earnings - Defense World
Squarepoint Ops LLC Cuts Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
ZURA Announces Upcoming Conference Call Hosted by Piper Sandler - GuruFocus
ZURA Announces Upcoming Conference Call Hosted by Piper Sandler | ZURA Stock News - GuruFocus
Two Sigma Advisers LP Invests $32,000 in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Northern Trust Corp Has $1.01 Million Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Consensus Target Price from Analysts - Defense World
Zura Bio to Present at the Jefferies Global Healthcare Conference - Yahoo Finance
Zura Bio to Present at the Jefferies Global Healthcare Conference 2025 - BioSpace
Zura Bio shareholders approve board nominees and auditor - Investing.com Australia
Zura Bio shareholders approve board nominees and auditor By Investing.com - Investing.com South Africa
Q1 Earnings Forecast for Zura Bio Issued By HC Wainwright - Defense World
Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa - Clinical Trials Arena
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment - Investing.com Australia
Zura Bio begins phase 2 trial for hidradenitis suppurativa treatment By Investing.com - Investing.com India
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):